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Highlights 
 
Meta-analysis of pain studies comparing parkinsons disease (PD) vs. healthy controls 
 
PD patients demonstrate hypersensitivity to pain (hyperalgesia) 
 
Hyperalgesia greatest during unmedicated OFF states 
 
Evidence supports dopamine deficiency as an underlying mechanism  
 
Hyperalgesia could contribute to onset/intensity of clinical pain in PD 
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Abstract 
While hyperalgesia (increased pain sensitivity) has been suggested to contribute to the 
increased prevalence of clinical pain in Parkinson’s disease (PD), experimental research is 
equivocal and mechanisms are poorly understood. We conducted a meta-analysis of studies 
comparing PD patients to healthy controls (HCs) in their response to experimental pain 
stimuli. Articles were acquired through systematic searches of major databases from 
inception until 10/2016. Twenty-six studies met inclusion criteria, comprising 1,292 
participants (PD=739, HCs=553). Random effects meta-analysis of standardized mean 
differences (SMD) revealed lower pain threshold (indicating hyperalgesia) in PD patients 
during unmedicated OFF states (SMD=0.51) which was attenuated during dopamine-
medicated ON states (SMD=0.23), but unaffected by age, PD duration or PD severity. 
Analysis of 6 studies employing suprathreshold stimulation paradigms indicated greater pain 
in PD patients, just failing to reach significance (SMD=0.30, p=.06). These findings (a) support 
the existence of hyperalgesia in PD, which could contribute to the onset/intensity of clinical 
pain, and (b) implicate dopamine deficiency as a potential underlying mechanism, which 
may present opportunities for the development of novel analgesic strategies.  
Keywords: Parkinson’s disease, dopamine, pain, meta-analysis, systematic review.   
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1 Introduction 
Chronic pain is a common non-motor symptom of Parkinson’s disease (PD). A recent 
systematic review indicated a mean pain prevalence of 68% in PD patients [6], with another 
study finding that chronic pain complaints, especially musculoskeletal pain, were twice as 
likely and reported as twice as intense in PD patients compared to age-matched controls 
with other chronic disorders [42]. Pain often appears early in the development of PD and 
may be present years before clinical diagnosis [49]. Pain has been rated as the most 
burdensome non-motor symptom [7], and contributes to PD-related disability, sleep 
disturbance, and impaired quality of life [9, 19, 46]. Non-motor symptoms including pain are 
also a frequent cause of hospitalisation and institutionalisation of PD patients and can 
increase healthcare costs by up to four times [9]. Nevertheless, pain is a frequently 
overlooked symptom of PD, often unreported by patients unaware that painful symptoms 
are linked to the disease [36], and consequently under-treated [6] which can increase the 
overall burden of PD. This is especially unfortunate given that pain represents a non-motor 
symptom that is eminently treatable [8]. 
 
While pain in PD is often precipitated by muscular rigidity and/or postural abnormalities 
[22], neurodegenerative processes could potentially affect not only motor function, but also 
peripheral [43] and brain [19] pathways involved in pain processing. For example, 
degradation of dopamine-producing cells in the substantia nigra may impair natural 
analgesia by disrupting the dopamine-mediated descending pathways that block 
transmission of ascending nociceptive signals from the spinal cord [19]. A role of dopamine 
in pain is consistent with reduced pain sensitivity seen in schizophrenia [53], a disorder 
linked to dopamine dysregulation, and the possible partial restoration of normal pain 
thresholds in PD during functional ON states following treatment with dopaminergic agents 
[13]. 
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If pain processing is affected centrally in PD, as hypothesised, this could result in a 
generalised hypersensitivity to noxious sensations [13], which may influence the onset of 
and/or exacerbate painful symptoms in PD [6]. Evidence for this hypersensitivity is, however, 
inconsistent. While several studies have found increased pain sensitivity in PD patients 
compared to healthy controls (HCs) in response to noxious experimental stimulation [10, 32, 
39], others have failed to find such an effect [25, 35, 61]. This inconsistency may be 
influenced by methodological differences across studies, including variation in sample size, 
dopaminergic and analgesic medications, disease duration and symptom severity [19, 45]. 
Nevertheless, to our knowledge, there has been no systematic effort to synthesize available 
evidence from experimental studies and to explore potential sources of study heterogeneity 
using meta-analytic techniques. Examining the influence of dopamine medication may be 
especially revealing, both to provide evidence for possible mechanisms of action and for 
informing potential analgesic treatment. 
 
We therefore conducted a systematic review and meta-analysis of studies comparing PD 
patients and HCs in their response to noxious experimental stimuli to: (1) examine whether 
PD patients and HCs differ in their response to experimentally-induced pain; (2) quantify the 
magnitude of this difference; and (3) explore potential moderators of this association 
including dopaminergic agents, disease duration, and symptom severity. 
 
 
2 Method 
This systematic review and meta-analysis was conducted in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [37] and the 
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Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [52] for 
observational studies. An a priori established but unpublished protocol was followed. 
 
2.1 Eligibility criteria 
The following inclusion criteria were applied: (1) use of a group with primary (idiopathic) 
Parkinson's disease (PD), based on standardized diagnostic criteria (e.g. UK Brain Bank); (2) 
inclusion of a comparative healthy control (HC) group without PD; (3) application of an 
experimental pain stimulus; and (4) a quantitative assessment of pain. We excluded studies 
using participants with secondary Parkinsonism only (e.g. from toxin exposure) and those 
published in languages other than English. 
 
2.2 Search strategy 
EMBASE, MEDLINE and PsycINFO databases were independently searched by two reviewers 
(KG, TT) with the final search performed on 10th October, 2016. The following search terms 
were used: (Parkinson’s disease(MeSH) OR Parkinson’s) AND (pain(MeSH) OR pain OR 
nociception) to identify the largest possible pool of potentially eligible studies. The search 
results were a posteriori refined using limits of ‘human studies’ and ‘English language’. This 
search strategy was augmented through hand searching reference lists of included articles 
and relevant reviews. 
 
2.3 Study selection 
After removal of duplicates, two reviewers (KG, TT) independently screened titles/abstracts 
for eligibility, and resolved disagreements through consensus. The full-text of potentially 
eligible articles was then independently scrutinized by two authors (TT, BS). Following 
consensus, a full-list of eligible articles was defined. When a study provided insufficient data 
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for inclusion, corresponding authors were contacted up to 3 times over an 8-week period to 
request additional data. Of 8 author groups contacted, 6 [3, 25, 28, 41, 43, 54] provided data 
sufficient to permit study inclusion. 
 
2.4 Pain outcome variables 
The following pain outcomes were used: (1) pain threshold (the point at which pain is first 
reported), (2) pain tolerance (the point at which pain is reported as no longer tolerable), and 
(3) self-report ratings of pain intensity/affect. We used these multiple outcomes to assess 
whether different aspects of the pain experience were selectively affected in PD. Threshold 
involves low-intensity pain and is influenced primarily by sensory processes (e.g., localization 
and initial detection), whereas tolerance is a suprathreshold measure more strongly 
influenced by affective mechanisms [2]. Pain rating scales provide an easily interpretable 
index of subjective pain and typically assess sensory (e.g., intensity) or affective (e.g., 
discomfort) dimensions of pain on a VAS or numerical rating scale. 
 
Sensory threshold (the point at which sensation is first reported) was included as a 
secondary measure to examine whether PD was also associated with non-painful sensory 
impairment. As we only wished to examine direct measures of pain, we did not examine 
supplementary physiological data.  
 
2.5 Data Extraction 
Extraction and coding of study data was performed by two authors (TT, KG), on a 
standardized form adapted from our previous studies [53, 57]. The following data were 
extracted where available: (1) sociodemographic variables; (2) For PD groups: mean disease 
duration (years), symptom severity score, functional state (ON/OFF), body side tested 
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(least/most affected), diagnostic criteria used, cognitive impairment, usual treatment, % of 
sample with PD-based clinical pain; (3) pain outcomes and pain induction method. Means 
and standard deviations for each pain outcome were recorded, and any other available 
information that allowed effect size computation [33]. To reduce reporting bias, authors 
were contacted for statistical details when findings were simply reported as ‘non-
significant’. 
A number of decisions were made when computing effect sizes from extracted data. First, a 
few studies (k=3) provided data from multiple independent participant samples [3, 48, 61], 
e.g. with/without dyskinesia, and were treated as separate studies in the analysis [4]. 
Second, for one study that used a wide range of temperatures [41], only those eliciting a 
self-report of pain (47.5˚C and 49.5˚C) were included. Third, for studies (k=2) that reported 
the use of different noxious electrical frequencies [3, 10], the lowest frequency was 
arbitrarily selected, as there appears to be no persuasive evidence for a frequency effect 
[10]. Fourth, where studies performed repeated pain assessments on the same set of 
participants (e.g. across different stimuli), multiple effect sizes were computed for each 
assessment with any dependency across effect sizes modeled using robust variance 
estimation (RVE) (see Section 2.7.2). 
 
2.6 Study validity criteria 
Two authors (KG, TT) independently rated each study on several dichotomous validity 
criteria, with a third author (BS) available for mediation in the event of disagreement. We 
assessed case/control comparability and participant selection with 5 items from the 
Newcastle Ottawa Scale [62], and methodological soundness with 14 items based on 
Cochrane Collaboration principles as reviewed by Deeks at al. [14] (see Table 1). Overall 
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scores were not computed due to concerns over their interpretability [14], but the impact of 
poorly endorsed validity criteria was examined in moderator analysis. 
 
2.7 Statistical analysis  
 Effect size 2.7.1
A standardized mean difference (SMD) for PD vs. control groups was computed for each 
study using Hedges' g formula [4]. Hedges' g is equivalent to Cohen's d, but corrects for bias 
in small samples. Effect sizes can be interpreted as .20,.50 and.80 corresponding to small, 
medium and large effects respectively [12]. 
Effect size (ES) was coded so that positive values indicated higher pain in the PD compared 
to the HC group. 
 
 Meta-analysis 2.7.2
An overall summary effect size for each outcome was estimated using random-effects meta-
analysis. A random-effects model was chosen as heterogeneity was expected based on 
similar meta-analyses conducted for other disease conditions [53, 57]. Several studies 
reported multiple ES data from the same samples and a few studies used different PD 
sample but with the same control group comparisons. Conventional meta-analytic 
techniques that assume independence of effect sizes were therefore not considered 
appropriate. Instead, we used a robust variance estimation (RVE) method [29], which adjusts 
individual ES weights based on the degree of their dependency. We employed a relatively 
new version of RVE for correlated effect sizes, which provides reliable estimates even when 
relatively low numbers of studies are available. Simulation studies have demonstrated 
accurate estimation, provided that the adjusted RVE degrees of freedom (df) > 4 [58], and 
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this criterion is used here (df is larger when study number is high and when multiple effect 
sizes from a study are relatively independent). RVE estimates dependency from the data 
itself, and therefore is a superior approach to averaging across conditions, which results in 
both information loss and relies on a knowledge of the correlations of outcomes across 
conditions which are rarely reported [20]. 
Separate analyses were conducted for OFF/ON functional states, to examine whether pain 
sensitivity is altered by treatment (typically dopaminergic medication). For the specific 
outcome of pain ratings, we only examined k=5 out of 7 studies where stimulation intensity 
was identical for both the PD and control groups (i.e., where a fixed-intensity/fixed-time 
paradigm was used), to avoid any confounding of group differences in pain ratings with 
group differences in stimulation intensity. 
 
 Meta-regression analyses 2.7.3
If effect sizes showed moderate or greater inconsistency across studies as assessed by 
Higgin’s I2 [30], with values of 25%, 50% and 75% corresponding to low, moderate and high 
inconsistency, meta-regression was conducted to identify possible underlying sources of 
variation. 
First, we examined symptom severity (as measured by the UPDRS-III), disease duration 
(years) and, for pain threshold, the assessment method (limits vs. constant/adjusted stimuli) 
as primary moderators, based on a rationale defined a priori. Greater symptom severity and 
longer disease duration likely to reflect increased neurodegeneration and therefore may be 
associated with a greater degree of abnormal pain perception. In addition, the methods of 
limits (where intensity increases to a pre-defined limit) involves a reaction time artefact (e.g. 
from pressing a button) which could artificially inflate threshold times and underestimate 
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true levels of pain selectively for PD patients due to motor impairment [13]. Conversely, the 
methods of constant stimuli/adjustment (where constant temperatures are gradually 
adjusted) [see 64] contains no reaction time component. 
Secondary moderators were study gender composition, age, stimulus modality, PD side 
subject to pain testing (least/most affected), anatomic site subject to pain testing, and 
sample percentage experiencing PD-based pain complaints. These variables were examined 
to provide preliminary data on any potential moderating influence, as all have been 
suggested as possible influences [19]. Additionally, meaningful study validity criteria were 
assessed as moderators, such as case and control selection, criteria-based PD diagnosis, 
explicit mentioning of disallowing pain medications. Finally, where the endorsement of 
important validity criteria varied across studies, the influence of these criteria as potential 
moderators of effect size was also assessed. 
 
2.8 Publication bias 
Publication bias was examined through visual inspection of funnel plots of mean study ESs 
against standard errors.  Any visual asymmetry resulting from the absence of small sample 
studies with small ESs can suggest possible publication bias. Asymmetry was also tested 
statistically with Egger’s bias test [17] with p<.05 indicating asymmetry. If present, a revised 
effect size assuming the presence of publication bias was computed using the trim and fill 
method [16].  
All analyses were performed using the robumeta package [20] in R [47]. 
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3 Results 
3.1 Study selection  
3047 unique hits were identified through database searches, with 6 additional records 
identified through manual searching of reference lists. Following the initial screening of 
abstracts, 47 articles were retained for full text review of which 21 were excluded, resulting 
in a total of 26 studies retained for analysis (Figure 1).   
 
-- FIGURE 1 ABOUT HERE -- 
 
3.2 Participant characteristics 
The 26 retained studies provided aggregated data for N=1292 participants, consisting of 739 
patients and 553 HCs. The mean study age (k=26 studies) was 63.8 years (SD=3.0, range of 
means=58.8-69.9 years) for the aggregated PD sample, and 62.4 years (SD=3.9, range of 
means=54.8-71.4 years) for the aggregated HC sample. The PD sample consisted of 35.7% 
females and the HC sample consisted of 42.7% of females (k=26).  
For the PD sample, mean disease duration (k=25) was 7.1 years (SD=3.4, range of means= 
1.8 - 15.5). Symptom severity (k=25) was most commonly measured with the original 
UPDRS-III Motor Examination scale [18] and was assessed during both ON (k=19; UPDRS-III 
M=21.8) and OFF (k=13; UPDRS-III M= 27.0) functional states. ON states were achieved with 
anti-Parkinson medication (k=18) or deep brain stimulation (k=1).  
A diagnosis of PD was based on UKBBC (k=18), ICD-10:G20 (k=1), Gelb NINDS guidelines 
(k=1) or was simply reported as a clinical diagnosis of PD (k=6). Medication data (k=24) 
included a single study which used a medication-naïve patient sample [56], while 23 studies 
reported regular usage of anti-Parkinson medication (L-DOPA with/without other 
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medication) by some or all enrolled patients (M=95%, study range=67-100%). Most studies 
(k=22) specified a minimum level of cognitive functioning for inclusion in the study, with 
scores>=25 on the Mini-Mental State Examination being the most extensively used inclusion 
criterion (k=15). 
Presence or absence of a primary chronic pain condition was reported by 13 studies. Of 
these, 12 reported no co-occurring chronic pain conditions and a single study reported that 
2 patients may have exhibited chronic low back pain. The mean study percentage of PD 
patients reporting secondary pain complaints attributable to PD (k=18) was 48%. 
 
3.3 Study characteristics  
Of the 26 studies, 15 were conducted in Europe, 6 in Asia, 2 in Oceania and 1 in each of 
North America, South America and Africa. All studies reported the method of pain induction 
and functional state during testing. Pain induction methods comprised heat (k=16), electrical 
(k=10), cold (k=7), pressure (k=6) and laser (k=1). Location of pain induction (k=24) for 
patients was on the most affected body side (k=9), least affected side (k=3) or the left or 
right side (k=12), and was applied to the hand (k=13), forearm (k=10), leg (k=10), face (k=2), 
neck (k=1), head (k=1) or upper arm(k=1). Pain testing was performed during the ON state 
(k=19), the OFF state (k=18), with 11 studies having assessed pain during both states in a 
repeated-measures design. For ON states, pain testing was usually conducted within the first 
hour of treatment initiation, with the presence of ON states confirmed by a reduction in 
UPDRS-III motor scores in all 7 repeated-measures design studies that assessed this. 
The majority of studies used pain threshold (k=21) as the method of pain assessment (k=11 
method of limits, k=7 method of levels/adjustment, k=3 not stated), with other outcomes 
including pain intensity ratings (k=7), pain tolerance (k=3) and threshold for moderate pain 
(k=3), with several individual studies employing multiple induction and assessment methods. 
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Nine studies also assessed sensory threshold. Aside from one study that included only drug-
naïve patients [56], OFF states were achieved by the withdrawal of dopaminergic 
medication, with pain testing usually taking place after a >= 12-hour washout period. 
A summary of the key characteristics of the 26 individual studies is presented in Table 1. 
 
3.4 Study validity criteria  
Acceptable agreement across the two raters was found for most items (Kappa=0.77-1.00) 
except for those with high rates of endorsement (min Kappa=0.25). High endorsement rates 
can result in low kappa values due to marginal homogeneity [27] and thus percentage 
agreement across raters was computed, with resultant percentages indicating good 
agreement (>87%) for those items. Complete consensus was reached whenever any 
disagreement occurred (see Appendix S1 for all item ratings).  
Ratings indicated methodological soundness (e.g., reporting of functional state during 
testing, complete data provided, clear description of procedures) for the majority of studies 
(>85% for most criteria). Most studies excluded patients with comorbid depression (77%) or 
somatosensory disorder (73%), with 42% explicitly specifying that use of pain medication 
(<24hrs) was an exclusion criterion. Low endorsement of ‘selection of PD cases (23%) and 
controls (27%) validity criterion reflected limited detail on recruitment methods; although 
studies did generally state the name of the recruiting hospital and provide good descriptions 
of characteristics of controls, usually matching cases and controls either experimentally or 
by statistically controlling for age/gender (77%).   
Some statistical inconsistencies were noted. One study [43] reported implausible pain 
thresholds (9.1-12.4˚C) for heat stimulation (values for other stimuli were plausible), and a 
further study [48] reported means and SDs for pain threshold highly inconsistent with 
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reported p-values (even when SDs were treated as SEMs), and so this specific data were 
excluded.  
 
3.5 Meta-analysis results 
 Pain threshold 3.5.1
Pain threshold data was examined for k=20 studies comprising a total sample of N=926 
(n=577 PD, n=473 HCs), with PD patents assessed during both OFF (k=14; N=728) and/or ON 
(k=13; N=617) states. Seven repeated-measures studies provided pain threshold data for 
both ON and OFF states.  
Meta-analysis of pain threshold, aggregating data from both ON and OFF states, found 
significantly lower overall pain threshold (i.e., greater pain sensitivity) in PD patients 
compared to HCs (SMD=0.37, CI95[0.16, 0.57], p=.001). Moderate to high heterogeneity 
(I2=63%) was observed and k=16 of 20 studies reported lower pain thresholds in PD. 
When separate meta-analyses were performed for ON and OFF state data, significantly 
lower pain thresholds in PD patients compared to HCs were found for the OFF state (k=14; 
SMD=0.51, CI95[0.23, 0.79], p=.002), along with moderate-high heterogeneity (I
2=64%). For 
ON state data, lower overall pain threshold in PD was also found but with a reduced effect 
size (k=13; SMD=0.23, CI95[0.02, 0.45], p=.04) and moderate heterogeneity (I
2=49%). A forest 
plot of pain threshold data for the OFF state is provided in Figure 2. 
 
-- FIGURE 2 ABOUT HERE – 
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Funnel plots of pain threshold data revealed no obvious asymmetry for data from either ON 
or OFF states, corroborated by non-significant values for Egger's asymmetry test (OFF: 
z=0.30, p=.76; ON: z=0.42, p=.67), consistent with a possible lack of publication bias.  
 
 Suprathreshold pain response 3.5.2
Three studies reported pain tolerance data, and 3 other studies reported 'threshold to 
moderate pain' (where participants were told to withdraw from noxious stimulation when 
experiencing moderate pain). Both measures were collapsed to a single suprathreshold pain 
category to maximize power (three studies is insufficient for RVE analysis). The 6 combined 
studies provided aggregate data for 442 participants (n=288 PD patients, n=154 HCs). Pain 
assessment occurred during both ON (k=5) and OFF states (k=4), with 3 studies providing 
data for both states.  
Meta-analysis of overall suprathreshold data found lower tolerance to suprathreshold pain 
(suggesting greater sensitivity) in PD patients, but this just failed to achieve statistical 
significance (SMD=0.30, CI95[-0.01, 0.61], p=.06). Analysis of different functional states 
indicated lower tolerance to suprathreshold pain during OFF (k=4; SMD=0.44, p=.04) states 
but not during ON (k=5; SMD=0.15, p=.28) states. For analysis of OFF state data, population 
confidence intervals (and thus p-values) may be wider or narrower [58] as the adjusted df<4.  
Low heterogeneity was observed in all instances (I2=4-27%). 
 
A funnel plot of overall suprathreshold data suggested asymmetry due to the presence of a 
small sample study with a large negative effect size. Some indication of possible asymmetry 
emerged from Egger’s test, which failed to achieve significance (but is also likely to be 
underpowered with only 6 studies), z=1.90, p=.054, A revised estimate using trim and fill 
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methods suggested a slightly larger effect size (SMD=0.36, p=.01) if publication bias is 
assumed. 
 
 Other outcomes: Pain ratings and sensory threshold 3.5.3
The adjusted df from RVE meta-analysis of pain ratings and sensory threshold were <4 
(reflecting both limited number of studies using these assessment methods and data 
dependency), which precluded reliable estimation of ESs [58] for these outcomes. 
 
3.6 Meta-regression analyses: pain threshold 
Meta-regression analyses were conducted to identify underlying sources of heterogeneity in 
ESs across pain threshold studies (other pain outcomes were not examined due to limited 
data not meeting RVE requirements). Functional state (ON/OFF) was included as an 
additional variable in each analysis to maximise power by allowing use of all pain threshold 
data (i.e. from both ON and OFF states), and given that functional state during testing is 
likely to represent a substantial source of variation in ES across studies that should be 
controlled for as a possible confounder. In addition, including functional state as a 
moderator allows the direct assessment of whether differences across ON vs. OFF states 
identified in the meta-analysis (Section 3.5.1) were significant. 
 
 PD severity 3.6.1
We examined whether reduced pain threshold (greater pain sensitivity) in PD was 
exacerbated in patients with more advanced disease states, by including disease duration 
and UPDRS-III scores as moderators in separate analyses. Results indicated that differences 
PARKINSON’S DISEASE AND PAIN 
 
 
19 
between PD and controls in pain threshold were not significantly influenced by disease 
duration (k=19; B=.035, p=.24) or UPDRS-III symptom severity (k=19; B=.006, p=.71).  
Results also indicated that effect size was significantly larger (k=19; ΔSMD=0.33, CI95[0.02, 
0.64], p=.039) for OFF (B=0.58) than ON (B=0.25) states. This pattern of results was 
reproduced (k=19; ΔSMD=0.33, CI95[0.02, 0.66], p=.041), when analysis was restricted to ON 
states achieved through dopamine medication only (i.e. the single deep brain stimulation 
study was excluded). 
 
 Method of assessment 3.6.2
Entering assessment method (limits vs. levels/adjustment) as a moderator in meta-
regression of pain threshold revealed that the difference in pain threshold between PD 
patients and controls was larger when the method of levels/adjustment was used, although 
this failed to reach statistical significance (k=18; ΔSMD=.34, p=.061).  
 
 Secondary moderators 3.6.3
Separate meta-regression analyses were conducted to explore other moderators specified in 
section 2.7.3. As 15 pain threshold studies explicitly stated the use of established diagnostic 
criteria and 5 studies did not provide information, we also examined this variable as a 
potential moderator. Given limited data for certain anatomic categories, we collapsed data 
to form two broad anatomic categories of arm (forearm, upper arm, hand) and leg (leg, 
foot). For the multiple categorical variable of stimulus modality, a no-intercept model was 
analysed so that each coefficient represented the absolute ES for each stimulus modality 
(rather than the difference in ES between that modality and an arbitrary reference 
modality).  
PARKINSON’S DISEASE AND PAIN 
 
 
20 
No evidence was found for moderating effects of studies’ gender composition (k=20; p=.38), 
mean study age (k=20; p=.62), affected vs. non-affected side tested (k=9; p=.91), anatomic 
site tested (k=17; p=.43) or diagnostic criteria provided (k=20; p=.55). For stimulus modality 
(k=20), however, PD patients demonstrated lower pain threshold than HCs in response to 
cold (SMD=0.62, p=.011), electrical (SMD=0.53, p<.001) and pressure (SMD=0.41, p=.055) 
stimuli, but not heat stimuli (SMD=-0.05, p=.79). PD-related pain could not be reliably 
assessed as a moderator, as the adjusted df was <4 [58]. 
 
 Study validity criteria 3.6.4
Given low endorsement for validity criteria of selection of cases/controls and reporting of 
pain medication use (Section 3.4), these variables were entered as moderators in separate 
meta-regression analyses of pain threshold. Neither case selection (p=.79) or control 
selection (p=.68) significantly moderated the ES. Differences in pain threshold between PD 
patients and controls were amplified in studies explicitly stating that participants were not 
using pain medication, although this did not achieve statistical significance (ΔSMD=.40, 
p=.052). 
 
3.7 Repeated-measures studies comparing ON vs. OFF states 
As previous analyses (Section 3.6.1) revealed that differences between PDs and controls 
were reduced during the ON state, we conducted a stricter evaluation by repeating the 
analysis including only the 7 studies that directly compared ON vs. OFF in a repeated-
measures designs to ensure superior control of confounds. Results were in line with previous 
findings (section 3.6.1), with differences in pain threshold between PD patients and HCs 
attenuated during ON states (k=7; ΔSMD =-0.25, CI95[-0.11, -0.38], p=.004). Removal of two 
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studies that did not randomize/ counterbalance ON/OFF state or failed to test HCs at 
equivalent intervals, had little impact on results (k=5; ΔSMD=-0.22, p=.045). Only 4 studies 
provided L-DOPA dosages during ON states, which was not sufficient to meet requirements 
for RVE meta-regression. 
 
4 Discussion 
The current meta-analysis is the first to examine whether patients with PD exhibit increased 
pain sensitivity compared to HCs and to investigate potential moderators. Our 
comprehensive analysis of 26 studies, primarily assessing pain threshold, with a combined 
total of 739 PD patients and 553 controls yielded several key findings: (1) Overall pain 
threshold was lower in PD patients (indicating greater pain sensitivity) compared to HCs; (2) 
Suprathreshold pain was lower in PD patients, although this narrowly failed to reach 
significance; (3) Abnormal pain thresholds in people with PD during OFF states (SMD=0.51) 
were significantly diminished, but not completely normalized during ON states (SMD=0.23) 
produced by dopaminergic medication; (4) Abnormal pain thresholds were not significantly 
influenced by symptom severity, disease duration, sex or age; (5) While most (16/20) 
individual studies indicated lower pain threshold in PD, moderate to high variation in effect 
sizes suggests that other, unidentified variables could influence abnormal pain responses in 
PD. 
 
4.1 Pain hypersensitivity in PD and clinical implications 
Results from our meta-analysis provide evidence that patients with PD demonstrate greater 
sensitivity to noxious stimulation compared to HCs, which seem to be independent of age 
and sex, and which occur for most types of aversive stimuli. Although no overall differences 
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were found for heat stimulation, the post-hoc nature of this result means any conclusions of 
modality-specific nociceptive processing abnormalities in PD should be made extremely 
cautiously and would require independent replication.  
Taken together, these results suggest that the increased prevalence and intensity of clinical 
pain complaints in PD could be, at least in part, influenced by abnormal nociceptive 
processing. In particular, these results could explain the increased prevalence of non-
musculoskeletal pain complaints (e.g., neuropathic pain), which do not obviously directly 
result from motor dysfunction. Although care must be taken in translating effect sizes from 
experimentally-induced pain to real-life pain experiences, the fact that an SMD=0.51 (in 
medication-free OFF states) can be classified as a moderate effect [12], provides some 
preliminary indication that the impact of PD on pain complaints outside of the laboratory 
may not be trivial. 
There is also some tentative evidence to suggest that the true extent of increased pain 
sensitivity could be underestimated by the moderate effect size we observed. Studies that 
explicitly stated that participants were not receiving pain medication (with PD patients 
generally being more likely to regularly use painkillers) were linked to a larger effect size (an 
SMD increase by 0.40). In addition, studies employing the methods of levels/adjustment, 
which has been argued to give a more accurate estimate of pain threshold than the method 
of limits due to a reduced reaction time artefact, also demonstrated a larger effect size (an 
SMD increase by 0.34). It is important that these findings are treated cautiously, as although 
suggestive, neither subgroup analysis reached statistical significance (p=.052-.061). 
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4.2 Role of dopamine 
The partial normalisation of the atypical pain thresholds in PD resulting from dopaminergic 
medication appears to be a robust finding, which was observed when all studies were 
examined and when only repeated-measures studies, which provide superior control of 
potential confounds, were included. This partial normalisation of pain threshold has a 
number theoretical and clinical implications which warrant further elaboration. 
First, this finding offers indirect evidence for an underlying role of dopamine depletion in 
pain hypersensitivity in PD. Although identifying exact underlying mechanisms is difficult 
from the available data, dopamine could elicit pain hypersensitivity either indirectly through 
modulatory effects on affective pain processing and/or directly by affecting neuronal activity 
at key pain-modulating areas in the brain such as the thalamus, basal ganglia, insula, 
anterior cingulate cortex and periaqueductal grey [19, 31]. Reduced dopaminergic 
neurotransmission may impair natural analgesia through a decreased activation of 
dopamine-mediated pain inhibitory pathways. These descend from the substantia nigra to 
the substantia gelatinosa in the spinal cord and inhibit transmission of ascending nociceptive 
signals [19]. This direct role of dopamine is consistent with PET studies in healthy 
participants that show an association between greater subjective pain and decreased 
dopamine activity [13], the diminished pain response seen in schizophrenia [53] a disorder 
linked to aberrant dopaminergic neurotransmission, and evidence from animal models 
suggesting a role of dopamine in chronic regional pain syndrome [63]. Experimental research 
on pain in PD patients assessing the effect of pro-dopaminergic and antidopaminergic states 
or medications could help further elucidate the role of dopamine in pain perception.  
Second, if attenuation of pain can be achieved through dopaminergic medication, this 
suggests that the development of classes of novel compounds that efficiently target 
dopamine pain-inhibitory pathways may have potential as effective analgesics. Such 
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compounds may be effective analgesics both for PD and for other painful disorders linked to 
disrupted endogenous dopamine activity such as fibromyalgia, burning mouth syndrome 
and painful diabetic neuropathy [31, 63]. Furthermore, if the suggestion that the underuse 
of conventional painkillers in PD patients is attributable to poor efficacy in this group [44], 
such medications could provide potentially superior alternatives. The utility of such 
analgesics could even extend to conventional treatment in healthy individuals with pain. 
While the role of opioids and non-dopaminergic (e.g. noradrenergic or serotoninergic) 
pathways is well recognised, the current findings further suggest a meaningful role for 
dopamine-mediated analgesia and may provide the impetus for further study involving 
preclinical models and neuroimaging techniques in humans. 
 
4.3 Partial pain threshold normalization 
The fact that dopamine medication diminished but did not appear to completely normalise 
pain threshold, suggests that additional mechanisms are likely to contribute to pain 
hypersensitivity in PD. Although it is difficult to identify such mechanisms from the current 
available data, these could include a loss of epidermal nerve fibres [43] or deficiencies in 
other, non-dopaminergic pain pathways. An alternative explanation is that pain 
hypersensitivity is entirely mediated by dopamine deficiency in PD but that study medication 
dosages were insufficient to restore dopamine neurotransmission to normal physiological 
levels. Due to insufficient available data, we were not able to assess whether higher L-DOPA 
dosages were associated with greater normalisation of pain threshold. 
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4.4 Independence of motor impairment and pain  
One notable finding was that pain sensitivity did not increase with increasing disease 
severity or duration. While this contrasts with clinical surveys which have shown the 
frequency and intensity of pain to be greater in advanced-stage compared to early-stage PD 
[59], this research refers primarily to musculoskeletal pain. While disease progression would 
be expected to intensify this type of pain due to increasing muscle rigidity or postural 
abnormalities [13], our findings suggest that changes in sensitivity to noxious input may 
occur early on and be relatively independent of motor function degradation. 
4.5 Limitations 
Whilst these data provide novel insights into altered pain perception in PD, some limitations 
should be noted. Firstly, findings are based primarily on pain threshold which was the most 
commonly studied pain outcome. Although an established measure of pain sensitivity, pain 
threshold represents pain at the lower end of the intensity continuum and cannot be 
automatically generalised to more intense levels of clinical pain. Second, although adequate 
data was available for meta-regression, genuine moderating effects of variables (e.g. disease 
duration) that were non-significant cannot be dismissed, and may be detectable with more 
available data; especially if the magnitude of these effects is small. Third, although exclusion 
of PD patients with cognitive impairment in primary studies was necessary to maximise 
adherence to experimental requirements, current findings should be necessarily restricted 
to PD patients who have relatively preserved overall cognition [21]. 
 
4.6 Future research directions 
Despite these limitations, the current findings provide strong support that individuals with 
PD exhibit greater sensitivity to noxious stimuli than HCs, based on laboratory studies that 
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provide a control of potential confounders not easily achievable in clinical settings. Future 
studies are needed to help establish whether pain hypersensitivity in PD extends to 
suprathreshold levels of pain, and insights may also be gained from the use of ischemic and 
dermal capsaicin experimental pain models that evoke several aspects of chronic pain whilst 
preserving strict experimental control [50]. More research involving preclinical models and 
neuroimaging techniques in humans would also help to elucidate potential mechanistic 
pathways underlying altered pain perception in PD. 
 
4.7 Conclusions 
To the authors’ knowledge, this is the only published meta-analysis of studies comparing PD 
patients with healthy controls in their response to controlled experimental pain stimulation. 
Results indicate significantly lower pain threshold in PD patients (indicative of greater pain) 
in the OFF state compared to controls. This was partially (but not completely) normalized by 
dopaminergic medication, suggesting that disruption of dopamine pain pathways may 
contribute to abnormal pain processing. These findings suggest that PD may confer a 
hypersensitivity to nociceptive information that could both exacerbate the musculoskeletal 
pain resulting from motor rigidity and abnormal posture control, and contribute to the less 
common but nevertheless troubling non-musculoskeletal pain complaints that occur in PD. 
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Online Supplementary Material 
Appendix S1. Endorsement of validity criteria (1=criteria satisfied, 0=criteria not satisfied) 
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Allen at al (2016) 1 1 0 0 0 0 1 1 1 1 1 1 1 0 1 1 0 0 0 
Mylius et al (2016) 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
Priebe et al (2016) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 
Ascherman et al (2015) 1 1 0 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 0 
Chen et al (2015) 0 1 0 1 1 0 1 1 1 1 1 1 0 1 1 1 0 1 1 
Grashorn et al (2015) 1 1 0 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 0 
Tan et al (2015) 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
Takeda et al (2014) 1 1 0 0 1 0 0 1 1 1 1 1 1 1 1 1 0 1 0 
Granovsky et al (2013) 1 1 0 0 0 1 1 1 1 1 1 1 0 1 1 1 0 0 1 
Hara et al (2013) 0 1 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 
Ciampi de Andrade et al (2012) 1 1 0 0 1 1 1 1 1 1 0 1 1 0 1 1 0 1 1 
Stamelou et al (2012) 1 1 0 0 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 
Vela et al (2012) 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
Maruo et al (2011) 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 0 0 0 
Mylius et al (2011) 1 1 0 0 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 
Zambito-Marsala et al (2011) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 
Nandhagopal et al (2010) 1 0 0 0 0 1 1 1 1 0 1 1 1 0 1 1 1 1 1 
Mylius et al (2009) 1 1 0 0 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 
Lim et al (2008) 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 
Nolano et al (2008) 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 0 0 1 
Gerdelat-Mas et al (2007) 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Schestatsky et al (2007) 0 1 1 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 
Vela et al (2007) 1 1 0 1 1 1 1 1 1 0 1 1 0 1 1 1 0 1 1 
Brefel-Courbon et al (2005) 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 1 
Djaldetti et al (2004) 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 0 0 1 1 
Massetani et al (1989) 1 1 0 0 0 1 1 1 1 0 1 0 0 1 1 1 0 1 0 
Mean Item Endorsement 0.88 0.96 0.23 0.27 0.69 0.88 0.92 1 0.92 0.73 0.96 0.96 0.77 0.85 0.88 0.92 0.42 0.77 0.73 
Item Key: 1-Was there a clear specification of study objectives?; 2-Is the definition of PD adequate?; 3-Representativeness of PD cases; 4-Selection of Controls; 5-Definition of Controls; 6-Was 
there a clear description of the inclusion and exclusion criteria?; 7-Was the method of pain assessment clearly described?; 8-Was the  method of pain induction clearly reported?; 9-Was it 
stated whether testing occurred in ON of OFF period?; 10-Comparability of cases and controls; 11-Were relevant participant characteristics adequately described?; 12-Was PD severity 
reported?; 13-Was cognitive impairment assessed?; 14-If any attrition, was drop-out relatively equal for both groups?; 15-Were complete outcome data available?; 16-Were statistics 
reported for significant and non-significant outcomes?; Were exclusion criteria reported for: 17-use of pain modifying medication, 18-presence of depression or other comorbid 
psychiatric/neurological diagnosis, 19- somatosensory disorder.  
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Figure captions 
Figure 1. PRISMA flow diagram 
Figure 2. Forest plot of pain threshold, with box sizes proportional to study weights (for studies with 
multiple outcomes, weights are divided evenly across outcomes).  
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Table 1. Summary of included studies. 
Study N - 
PD 
Duration 
years 
UPDRS-III ON/OFF 
state during 
pain testing 
Usual Medication N -
CON 
Modality Testing Site  Pain Measure 
Priebe et al (2016) [45] 23 8.1 18.4 (OFF) OFF 
ON 
Mixed (L-DOPA=1; DA agonists 
=5; L-DOPA + DA agonists =17; 
MAO inhibitors=9; COMT 
inhibitors=2; NMDA 
blockers=5) 
23 Heat 
Electrical 
Forearm 
Leg  
Pain Threshold 
Pain Threshold (NFR) 
Pain Intensity 
EMG response 
Mylius et al (2016) [40] 14 1.8 22.8 (ON) OFF NS but inc. L-DOPA 27 Heat  
Electrical 
Forearm 
Leg 
Pain Threshold  
Pain Threshold (NFR) 
Allen at al (2016) [1] 26 - 27.3
b (ON) ON NS 11 Pressure (type 
not stated) 
Upper Arm 
Leg 
Pain Threshold 
Ascherman et al (2015)-
a[3] 
  6  6.20 11.2 (ON) ON Mixed (levodopa, dopamine 
agonists, MAO and COMT-
inhibitors) 
 6 Heat  Forearm 
 
Pain Threshold (for moderate pain) 
Pain Intensity 
Ascherman et al (2015)-
b [3] 
  6  5.50 15.8 (ON) ON Mixed (as above)  6a Heat  Forearm 
 
Pain Threshold (for moderate pain) 
Pain Intensity 
Chen et al (2015) [10]  72  4.90 29.5 (OFF) 
23.1 (ON) 
OFF 
ON 
L-DOPA 35 Electrical Hand Sensory Threshold 
Pain Tolerance 
Grashorn et al (2015) 
[26] 
 25  3.70 24.1 (OFF) 
20.7 (ON) 
OFF 
ON 
Mixed (L-DOPA=4, L-DOPA+ 
MAO inhibitors=2, L-DOPA+ DA 
agonists=1; DA agonists =7; DA 
agonists+MAO Inhibitors =9; 
MAO inhibitors=2) 
30 Heat 
Cold pressor 
Forearm 
Leg 
 
Pain Threshold (for moderate pain) 
Pain Intensity 
 
Tan et al (2015) [56]  14  2.50 21.8 (OFF) OFF None 17 Heat Forearm 
 
Sensory Threshold 
Pain Threshold 
Pain Intensity 
Takeda et al (2014) [55]  23  5.60 27.0 (ON) ON Mixed (L-DOPA=4, L-DOPA+ DA 
agonists=11, MAO inhibitors=8) 
12 Electrical Hand 
Leg 
Pain Threshold (for moderate pain) 
Hara et al (2013) [28]  42  6.50 21.6 (ON) ON Mixed (L-DOPA, DA agonists, 
MAO inhibitors, catechol-
Omethyl transferase and 
amantadine) 
17 Electrical Face Pain Threshold 
Granovsky et al (2013) 
[25] 
 23  6.30 23.6 (ON) OFF 
ON 
Mixed (L-DOPA=11, DA 
agonists=17,  MAO 
inhibitors=19, Anticholinergics 
=8, Amantadine=14) 
19 Heat 
Pressure (von 
Frey filaments) 
Hand 
Forearm 
 
 
Pain Threshold 
Pain Intensity 
Vela et al (2012) [60]  18 11.60 34.5 (OFF) 
22.1 (ON) 
OFF 
ON 
Mixed (L-DOPA, DA agonists) 18 Pressure 
(algometer) 
Heat 
Cold 
Neck 
Head 
Hand 
Leg 
Pain Threshold 
Ciampi de Andrade et al 
(2012) [11] 
 25 15.10 42.7 (OFF) 
25.8 (ON – 
via DBS) 
OFF 
ON 
L-DOPA 35 Heat 
Cold 
Pressure (von 
Frey filaments) 
 
Hand 
 
Sensory Threshold  
Pain Threshold 
Pain Intensity 
Stamelou et al (2012) 
[51] 
 19  6.70 22.4 (ON) OFF L-DOPA (no details on other 
medications) 
17 Heat 
Electrical 
 
Forearm 
Leg  
Pain Threshold (NFR) 
Pain Threshold 
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Study N - 
PD 
Duration 
years 
UPDRS-III ON/OFF 
state during 
pain testing 
Usual Medication N -
CON 
Modality Testing Site  Pain Measure 
Mylius et al (2011) [38]  29  7.40 25.6 (ON) OFF L-DOPA (no details on other 
medications) 
27 Electrical 
Heat 
Forearm 
Leg  
Pain Threshold (NFR) 
Maruo et al (2011) [34]  17 15.50 36.3 (ON) ON L-DOPA, DA agonists (no details 
on other medications) 
14 Cold  
Heat 
Hand 
 
Sensory Threshold  
Pain Threshold 
Zambito-Marsala et al 
(2011) [65] 
106  5.70 23.5 (OFF) OFF Mixed (L-DOPA=38; DA 
agonists =19; L-DOPA + DA 
agonists =49) 
51 Electrical Hand 
Foot 
Sensory Threshold  
Pain Threshold 
Pain Tolerance 
Nandhagopal et al 
(2010) [41] 
 12  9.40 28.8 (OFF) 
15.0 (ON) 
OFF 
ON 
Mixed (L-DOPA with/without 
other medication=12) 
13 Heat  Forearm 
 
Pain Intensity 
Pain Unpleasantness 
Mylius et al (2009) [39]  15 11.00 28.3 (OFF) OFF Mixed 18 Heat 
Electrical 
 
Forearm 
Leg  
Pain Threshold  
Pain Threshold (NFR) 
Nolano et al (2008) [43]  18  7.60 26.6 (ON) ON Mixed (L-DOPA with/without 
other medication=14, None=4) 
54 Cold  
Heat 
Pressure 
(nylon 
monofilament) 
Hand 
Foot 
Sensory Threshold  
Pain Threshold 
Lim et al (2008) [32]  50  4.38 29.6 (OFF) 
21.3 (ON) 
OFF 
ON 
L-DOPA (no details on other 
medications) 
20 Cold pressor Hand Pain Threshold 
Pain Tolerance 
Gerdelat-Mas et al 
(2007) [23] 
 13  7.30 21.2 (OFF) 
10.8 (ON) 
OFF 
ON 
Mixed (L-DOPA and/or DA 
agonists) 
10 Electrical Leg Pain Threshold (NFR) 
Schestatsky et al (2007)-
a [48] 
  9  5.40 17.1 (NS) OFF 
ON 
NS but inc. L-DOPA  9 Heat 
Laser 
Hand Sensory Threshold 
Pain Threshold 
Schestatsky et al (2007)-
b  [48] 
  9  6.00 19.1 (NS) OFF 
ON 
NS but inc. L-DOPA  9a Heat  
Laser 
Hand Sensory Threshold 
Pain Threshold  
Vela et al (2007)-a [61]  25 11.38 24.6 (ON) ON NS 25 Pressure 
(algometer) 
Hand Pain Threshold 
Vela et al (2007)-b [61]  25  4.72 19.9 (ON) ON NS 25
a Pressure 
(algometer) 
Hand Pain Threshold 
Brefel-Courbon et al 
(2005) [5] 
  9  9.60 25.0 (OFF) 
15.0 (ON) 
OFF 
ON 
Mixed (L-DOPA and/or DA 
agonists) 
 9 Cold pressor Hand Pain Threshold 
Djaldetti et al (2004) 
[15] 
 51  5.30 24.0 (OFF) OFF Mixed (L-DOPA and/or DA 
agonists) 
28 Heat  
 
Hand Pain Threshold 
Massetani et al (1989) 
[35] 
 15  4.10 NA ON Mixed (L-DOPA with or without 
peripheral decarboxylase 
inhibitor=10, drug free=5)  
 8 Electrical Face Sensory Threshold 
Pain Threshold 
Pain Threshold (blink reflex) 
TOTAL 
for 26 studies 
739 M=7.10 
years 
ON: 
M=22.2 
yrs 
OFF: 
M=27.0 
yrs 
ON=19;  
OFF=18 
L-DOPA with/without 
others=23 
Not Stated =2 
None=1 
553 Heat=16; 
Electrical=1; 
Cold=7; 
Pressure=6;  
Laser=1 
Hand=13; 
Forearm=10; 
Leg=10; 
Face=2; 
Foot=2; 
Neck/Head/ 
Upper Arm=1 
Pain Threshold=21; 
Sensory Threshold=9; 
Intensity=7; Suprathreshold 
(moderate pain/tolerance)=6; 
Unpleasantness=1 
Key: NS=Not Stated, NFR=Nociceptive Flexion Reflex, DA=Dopamine, MAO=Monoamine oxidase, 
COMT=Catechol-O-methyltransferase, NMDA=N-methyl-D-aspartate 
aSame control group used for '-a' and '-b' studies 
bEstimated from MDS-UPDRS-III score of 33.8 using conversion formula [24] 
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Figure 1. PRISMA flow diagram 
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